BiOptic Inc., Hermo Electric, and GGA Sign MOU to Expand Presence in Japan’s Market

BiOptic Inc. (Stock Code: 6850) announced today (16th) that it has signed a Memorandum of Understanding (MOU) with Hermo Electric Co., Ltd. and GGA Corp. The three parties will combine their respective strengths to jointly expand into Japan’s biotechnology innovation and medical diagnostics markets, aiming to seize significant opportunities in the precision health sector.

BiOptic Inc. stated that this move follows a previous agreement signed last year with Hermo Electric and Otsuka Electronics for the joint promotion and sales of the Qsep Ultra biofragment analyzer and related reagent kits in the Japanese market, marking a further expansion of its presence in Japan.

Under the MOU, BiOptic Inc., Hermo Electric, and GGA Corp. will first establish a joint working group to address market demand in Japan, technological integration, regulatory issues, and more. Regular meetings will be held to formulate strategic plans, ensuring flexibility and sustainability in their collaboration. Specific technical and product development details will be outlined in a forthcoming formal agreement.

Founded 21 years ago with capillary electrophoresis technology, BiOptic Inc. has since expanded its product reach to over 60 countries worldwide. In recent years, to broaden the applications of its instruments, the company began developing diagnostic reagents even before the COVID-19 pandemic. In addition to completing reagents targeting specific genetic markers, it has integrated gene amplification and analysis capabilities with its proprietary reagents to launch an open genetic testing platform. This platform enables other reagent developers to rapidly and easily create highly accurate diagnostic products. The current three-party collaboration is built upon this foundation.

Hermo Electric Co., Ltd., a wholly-owned subsidiary of Hermo Group, primarily engages in electronic semiconductor import/export and domestic sales and has actively pursued new business ventures in recent years. BiOptic Inc. previously leveraged Hermo’s deep familiarity with the Japanese market and extensive business network to establish a three-party alliance with Otsuka Electronics. Building on this strong cooperation and experience, the partners are now further deepening their collaboration.

GGA Corp. specializes in the development of gene diagnostic tools and precision medicine services. With a globally positioned portfolio of pharmacogenomic patents, GGA has developed and commercialized various drug-gene testing products and diagnostic tools, establishing itself as a leader in the global pharmacogenomic testing market. GGA’s clear strategy in developing diagnostic targets, proven track record in obtaining medical testing certifications, and GMP-compliant manufacturing capabilities make it a solid partner for expanding into the global market.

President Eric Tsai expressed his enthusiasm for the new partnership with Hermo Electric and GGA. By combining BiOptic’s competitive and user-friendly testing platform, GGA’s strong expertise in reagent development, and Hermo’s robust distribution network, the collaboration leverages the unique advantages of each company in the biomedical field. The goal is to identify unmet needs in Japan’s health and wellness market and promote the localization of innovative technologies and products, thereby boosting market competitiveness and brand influence to create a win-win-win outcome.

In recent years, BiOptic Inc. has continued building its global sales network. President Eric Tsai noted that Asia has long been the company’s primary market. Through active participation in international exhibitions and events, BiOptic has significantly increased its brand visibility and successfully entered the European market, now its fastest-growing region. Currently, the company’s revenue mainly comes from Europe and Asia, making it unaffected by reciprocal tariffs imposed by the United States. In fact, since most competing products originate from the U.S., tariff barriers may actually enhance BiOptic’s competitiveness in other regions. Moving forward, the company will closely monitor U.S. tariff policy developments and adjust its market strategies accordingly to maximize profitability.